Study S001770

31P-MRS and MRI Imaging in Semaglutide Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07695454
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 10
Start: 2026-07-30
Primary completion: 2026-12-30
Lead sponsor: The Cleveland Clinic
Conditions: Type 2 Diabetes; BMI Greater Than 30
Interventions: RADIATION:31P-MRS and MRI
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Effects of semaglutide therapy on patients muscle mitochondrial function as quantified using phosphorous MR spectroscopy. [6 months]
Effects of semaglutide therapy on patients muscle fatty infiltration measured by MR relaxation time (T1, T2 and T1rho) mapping. [6 months]
Effects of semaglutide therapy on patients measured by hand grip. [6 months]
Effects of semaglutide therapy on patients measured by MRI. [6 months]
Effects of semaglutide therapy on patients muscle composition measured by MR relaxation time (T1, T2 and T1rho) mapping. [6 months]
Effects of semaglutide therapy on patients muscle composition measured by MR water-fat imaging. [6 months]
Effects of semaglutide therapy on patients muscle fatty infiltration measured by MR water-fat imaging. [6 months]
Effects of semaglutide therapy on patients muscle fatty infiltration measured by MR relaxation time (T1, T2 and T1rho) mapping [6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.